What is the appropriate oral antiviral regimen and supportive care for a patient with a genital herpes outbreak (first episode and recurrent) and oral herpes, and how should management be modified for immunocompromised, pregnant, or severe cases?

Management of Herpes Lesion Outbreaks

Oral Herpes (Cold Sores/Herpes Labialis)

For oral herpes outbreaks, initiate valacyclovir 2 g twice daily for 1 day (doses separated by 12 hours) at the earliest sign of prodromal symptoms or within 24 hours of lesion onset. 1

First-Line Episodic Treatment Options

• Valacyclovir 2 g orally twice daily for 1 day is the preferred regimen, reducing median episode duration by approximately 1 day and offering superior convenience. 1
• Famciclovir 1500 mg as a single oral dose provides equivalent efficacy to valacyclovir with single-day dosing. 1
• Acyclovir 400 mg orally five times daily for 5 days remains effective but requires more frequent dosing and may reduce adherence. 1

Critical Timing Considerations

• Treatment must begin during the prodromal phase (tingling, burning, itching) or within 24 hours of lesion appearance because peak viral titers occur in the first 24 hours; delayed initiation markedly diminishes efficacy. 1
• Patient-initiated therapy at first symptoms may prevent lesion development in some cases. 1

Suppressive Therapy for Frequent Recurrences

Patients experiencing ≥6 recurrences per year should receive daily suppressive therapy, which reduces outbreak frequency by ≥75%. 1

Suppressive Regimen Options

• Valacyclovir 500 mg once daily (increase to 1000 mg once daily for ≥10 recurrences per year). 1
• Famciclovir 250 mg twice daily as an alternative. 1
• Acyclovir 400 mg twice daily with documented safety for up to 6 years. 1, 2

Duration and Reassessment

• Safety is documented for acyclovir up to 6 years and for valacyclovir/famciclovir for 1 year of continuous use. 1
• After 1 year of suppressive therapy, discontinue treatment temporarily to reassess recurrence frequency, as outbreak rates naturally decline over time in many patients. 1, 2

---

Genital Herpes

First Episode (Primary Infection)

For first-episode genital herpes, prescribe acyclovir 400 mg orally three times daily for 7–10 days, or valacyclovir 1 g orally twice daily for 10 days, continuing until all lesions are fully crusted and healed. 1, 3

Alternative First-Episode Regimens

• Acyclovir 200 mg orally five times daily for 7–10 days. 3, 4
• Famciclovir 250 mg orally three times daily for 7–10 days. 3

Severe First-Episode Disease

• For severe first-episode genital herpes requiring hospitalization, initiate acyclovir 5–10 mg/kg IV every 8 hours until lesions begin to regress, then switch to oral therapy and continue until complete healing. 1

Recurrent Episodes

For recurrent genital herpes, initiate episodic therapy with valacyclovir 500 mg orally twice daily for 5 days at the first sign of prodrome or within 1 day of lesion onset. 3

Alternative Episodic Regimens for Recurrences

• Acyclovir 400 mg orally three times daily for 5 days. 3
• Acyclovir 800 mg orally twice daily for 5 days. 3
• Famciclovir 125 mg orally twice daily for 5 days. 3

Suppressive Therapy for Recurrent Genital Herpes

Patients with ≥6 genital herpes recurrences per year should receive daily suppressive therapy, reducing recurrence frequency by ≥75%. 2, 3

Suppressive Regimen Options

• Valacyclovir 500 mg once daily for patients with <10 recurrences per year. 2, 3
• Valacyclovir 1000 mg once daily for patients with ≥10 recurrences per year. 2, 3
• Acyclovir 400 mg twice daily with safety documented for up to 6 years. 2, 3, 5
• Famciclovir 250 mg twice daily as an alternative. 2, 3, 6

---

Immunocompromised Patients

Immunocompromised patients experience more severe, prolonged episodes with higher acyclovir resistance rates (7% versus <0.5% in immunocompetent hosts) and require higher doses or longer treatment durations. 1

Treatment Modifications

• Acyclovir 400 mg orally three to five times daily for oral or genital herpes, continuing until clinical resolution. 1
• For severe or extensive disease, initiate acyclovir 5–10 mg/kg IV every 8 hours until lesions regress, then switch to oral therapy. 1

HIV-Infected Patients

• Valacyclovir 500 mg twice daily for suppressive therapy in patients with CD4+ count ≥100 cells/mm³. 2
• Famciclovir 500 mg twice daily for 7 days for recurrent orolabial or genital HSV; severe episodes may require extended therapy. 1
• Twice-daily dosing is preferred over once-daily regimens in HIV-infected individuals. 2

---

Acyclovir-Resistant HSV

If lesions fail to improve within 7–10 days of appropriate antiviral therapy, suspect acyclovir resistance and switch to foscarnet 40 mg/kg IV every 8 hours until complete clinical resolution. 1, 2, 3

Resistance Patterns

• All acyclovir-resistant strains are also resistant to valacyclovir and exhibit cross-resistance to famciclovir. 2
• Resistance rates remain <0.5% in immunocompetent patients but rise to 5–7% in immunocompromised individuals. 1, 2

Monitoring During Foscarnet Therapy

• Assess baseline renal function before initiating foscarnet and monitor renal function and electrolytes (especially calcium and magnesium) at least once or twice weekly. 2
• Maintain aggressive hydration to mitigate nephrotoxicity. 2

---

Pregnancy

Acyclovir is the preferred antiviral during pregnancy, given the largest safety experience base; current registry data do not indicate increased risk for major birth defects. 2

Treatment Approach

• Episodic therapy for primary infection or recurrences may be offered during pregnancy, but routine suppressive therapy is not recommended. 2, 3
• Late-pregnancy acyclovir therapy suppresses genital herpes outbreaks and reduces the need for cesarean delivery. 2
• Women of childbearing age should disclose any history of genital herpes to healthcare providers before or during pregnancy. 2

---

Severe or Widespread HSV Infection

For extensive mucocutaneous HSV disease with widespread crusted lesions in immunocompetent adults, initiate valacyclovir 1000 mg orally twice daily for 7–10 days, continuing until all lesions are fully crusted. 1

Alternative Regimens

• Famciclovir 500 mg orally twice daily for 7–10 days. 1
• Acyclovir 400 mg orally five times daily for 7–10 days. 1

When to Escalate to IV Therapy

• For severe HSV requiring hospitalization, disseminated involvement (encephalitis, pneumonitis, hepatitis), or extensive disease in immunocompromised patients, initiate acyclovir 5–10 mg/kg IV every 8 hours until lesions regress, then switch to oral therapy. 1

---

Herpetic Gingivostomatitis

Mild Cases

• Acyclovir 20 mg/kg (maximum 400 mg/dose) orally three times daily for 5–10 days for mild symptomatic gingivostomatitis. 1

Moderate to Severe Cases

• Acyclovir 5–10 mg/kg IV three times daily until lesions begin to regress, then switch to oral acyclovir and continue until complete healing. 1

Supportive Care

• Apply white soft-paraffin ointment to lips every 2 hours. 1
• Use mucoprotectant mouthwash (e.g., Gelclair) three times daily. 1
• Benzydamine hydrochloride oral rinse or spray every 3 hours, especially before meals, for pain relief. 1
• Hydrogen peroxide 1.5% or chlorhexidine digluconate 0.2% oral rinse twice daily to reduce bacterial colonization. 1
• For severe pain, apply viscous lidocaine 2% (approximately 15 mL per application). 1

---

Renal Dosing Adjustments

• For creatinine clearance <30 mL/min, reduce valacyclovir to 500 mg every 24–48 hours; no adjustment needed for CrCl 30–49 mL/min. 2
• Assess renal function before initiating therapy in elderly patients (≥80 years) to allow appropriate dose adjustment. 1
• Advise adequate hydration to minimize nephrotoxicity risk. 2

---

Contagiousness and Transmission Prevention

• Patients remain contagious until all lesions are fully crusted, which is the standard clinical endpoint indicating substantial reduction in transmission risk. 1
• Valacyclovir shortens viral shedding time by approximately 21% (6.4 days versus 8.1 days with placebo). 1
• Avoid direct skin-to-skin contact with affected areas, kissing, oral sex, and sharing towels, utensils, or lip balm until lesions are completely crusted. 1
• Suppressive therapy reduces but does not eliminate asymptomatic viral shedding; transmission risk persists even while on treatment. 1, 2, 3
• Patients should abstain from sexual activity during active lesions or prodromal symptoms and use condoms for all sexual encounters with new or uninfected partners. 2, 3

---

Preventive Measures and Trigger Avoidance

• Apply sunscreen (SPF ≥15) or zinc oxide to lips before UV exposure to prevent UV-triggered recurrences. 1
• Counsel patients to identify and avoid personal triggers including ultraviolet light, fever, psychological stress, and menstruation. 1

---

Common Pitfalls to Avoid

• Do not rely on topical antivirals, which provide only modest benefit and are substantially less effective than oral therapy. 1, 3
• Do not discontinue antiviral therapy at exactly 7 days if lesions have not fully crusted; continue until complete healing. 1
• Do not use valacyclovir 8 g per day in immunocompromised patients due to risk of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. 2, 3
• Do not delay escalation to IV acyclovir in immunocompromised patients or those with severe disease. 1
• Do not fail to consider suppressive therapy in patients with ≥6 recurrences per year who could significantly benefit. 1